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ABSTRACT 
 
Rheumatoid arthritis (RA) is an uncurable auto-immune disease characterized by inflammation 
and tissue destruction in several joints. An early and adequate diagnosis are important to prevent the 
main symptoms, which are painful and swollen joints, morning stiffness, edema and progressive 
disability. Despite the improvement in therapeutic options, around 30% of patients discontinue treatment 
due to a weak clinical response, adverse effects or incapability to afford such expensive therapies. 
Therefore, an effective and safe therapy is desirable.  
Celastrol, a compound from the Chinese plant Trypterigium wilfordii Hook F., has revealed a 
remarkable outcome in the treatment of several inflammatory diseases. Recently, our group has proven 
its efficacy in the treatment of inflammatory signs and bone damage, with no short-term toxicity, when 
the compound is intraperitoneally administered in an early and late phases of arthritis in the adjuvant-
induced artritis (AIA) rat model. These data thus support the hypothesis that celastrol is a promising 
candidate for drug development for the treatment of RA. 
In the present study, our group focused on exploring the efficacy of orally administrated celastrol, 
in two different doses, and studying inherent toxicity in the same rat model of arthritis. The study intent 
to provide a rationale for setting dose levels for further preclinical studies.  
In order to evaluate ethanol as a suitable vehicle for the oral administration of celastrol in this set-
up, a group of AIA rats received ethanol 17% in PEG400 by gavage and was compared with arthtiric 
animals that did not receive ethanol. The absence of body weight loss in the animals that received ethanol 
and the lack of differences on disease course between the two groups allowed the use of ethanol as a 
solvent for celastrol. 
Hence, two groups of AIA rats were treated with celastrol orally at two different doses (5 or 7.5 
µg/g/day) starting 8 days after disease induction. Both celastrol-treated groups were compared with a 
group of arthritic-untreated and healthy rats which received vehicle (17% in PEG400) and water, 
respectively. All the animals were euthanized 22 days after disease induction and samples were collected 
to futher analysis. 
Our results showed that orally administered celastrol halts inflammation and decreases bone 
erosions in both dosages. Furthermore, our results also showed a reduction on the number of osteoclasts 
in celastrol-treated groups. However, significant toxic effects were observed in celastrol at 7.5 µg/g/day 
treated group. The other dose used in this study (5 µg/g/day) will be considered in future pre-clinial 
assessments conducted by our group. 
 
 
Keywords: Rheumatoid arthritis, celastrol, adjuvant-induced arthritis rat model, oral administration, 
dosage. 
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RESUMO 
 
A Artrite Reumatóide (AR) é uma doença autoimune, progressiva e crónica que se caracteriza por 
uma acentuada inflamação nas articulações com consequente reabsorção do osso e da cartilagem. Não 
existe cura e a atual estratégia terapêutica implica o diagnóstico e início de tratamento o mais cedo 
possível com vista à eventual remissão. Os sintomas iniciais incluem rigidez, inchaço e dor nas pequenas 
articulações que posteriormente alastram para as articulações maiores. 
Apesar da etiologia da AR não ser inteiramente conhecida, sabe-se que a perda de tolerância 
imunológica está associada à predisposição genética do individuo associada à exposição a fatores de 
risco como o tabagismo ou à possível ocorrência de um episódio estocástico que leve ao surgimento de 
autoanticorpos. A inflamação articular desenvolve-se devido à anormal infiltração de células do sistema 
imunitário na membrana sinovial levando à libertação de citocinas pro-inflamatórias, quimiocinas e 
moléculas de adesão celular que sustêm e perpetuam a inflamação. O microambiente rico em mediadores 
inflamatórios ativa os osteoclastos, células responsáveis pela reabsorção do osso, desequilibrando desta 
forma a homeostase óssea a favor da reabsorção. 
Apesar da recente evolução das estratégias de tratamento e do surgimento de novas terapêuticas, 
estas não são completamente eficazes e induzem efeitos adversos provocando a descontinuidade do 
tratamento em cerca de 30% dos doentes. Assim, continua a ser necessário o desenvolvimento de uma 
terapia eficaz, bem tolerada, e disponível para a generalidade da população. Com base nesta 
problemática o nosso grupo tem investigado um composto bioactivo da planta Trypterigium wilfordii 
Hook F., o celastrol. Este composto para além de revelar propriedades anti-inflamatórias, reduz e a 
reabsorção do osso e da cartilagem.  
Com o intuito de dar continuidade à investigação desenvolvida pelo nosso laboratório, o presente 
estudo tem como principal objetivo explorar a eficácia anti-inflamatória e de protecção óssea do 
composto quando administrado oralmente assim como investigar possiveis efeitos adversos. Para tal, 
foi utilizado o modelo de artrite induzida por adjuvante (AIA) em rato. Os animais artríticos foram 
divididos em grupos sendo que a um dos grupos foi administrado por gavagem (intragastricamente) 
5μg/g e a outro 7.5 μg/g diariamente de celastrol. Foi ainda utilizado como controlos um grupo de 
animais artríticos e um de ratos saudáveis, da mesma espécie e idade, que receberam veículo ou água, 
respectivamente. O estudo durou 22 dias sendo que o dia 0 corresponde ao dia da indução da doença, e 
o dia 8, fase em que se inicia o periodo agudo da artrite, foi o primeiro dia de tratamento (modelo 
terapêutico). De forma a avaliar o etanol como veículo foi administrado etanol a 17% em PEG400 a um 
grupo de animais artríticos e comparado com outro grupo de animais artríticos sem administração de 
veiculo. Todos os animais foram pesados ao longo do periodo experimental assim como medido o 
diâmetro da pata traseira esquerda e atribuído um score de acordo com a severidade da inflamação. 
O etanol não provocou diferenças significativas nos parâmetros acima indicados. A análise 
histopatológica feita às patas traseiras esquerdas destes animais revelou que o etanol não altera a 
progressão da doença caracteristica destes animais e não provocou uma diminuição do peso. Desta 
forma, foi possível utilizar o etanol como solvente do celastrol.  
Ambas as doses de celastrol administradas diminuíram significativamente a inflamação visível 
em todas as patas assim como o inchaço da pata traseira esquerda. Este resultado foi comprovado pela 
análise histopatológica. Ambas as doses de celastrol diminuíram significativamente a infiltração e 
proliferação celular assim como as erosões osseas.  
De modo a explorar a ação do celastrol na proliferação de células na sinovia e nas células de 
rearbsorção e formação óssea, foram marcados por imunohistoquimica o ki67 (marcador de células 
proliferativas na sinovia), osteocalcina (marcador de osteoblastos) e catepsina K (marcador de 
osteoclastos em reabsorção). Todos os biomarcadores foram significativamente reduzidos nos animais 
em que o composto foi administrado em comparação com os animais artríticos não tratados. Desta 
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forma, não só foi possível validar os efeitos anti-proliferativos do celastrol como também concluir que 
o celastrol atua no osso diminuindo as células de remodelação óssea presentes na articulação. Foi ainda 
avaliada a presença de macrófagos CD68+ na sinovia. A redução destas células na sinóvia funciona 
como biomarcador da resposta de novas terapeuticas para o tratamento da AR, quer em humanos quer 
em modelos animais. A sua diminuição significativa nos animais tratados permitiu validar o celastrol 
como candidato ao tratamento da artrite.  
Os efeitos do celastrol no osso foram validados pela análise no soro de CTX-I e P1NP, marcadores 
de reabsorção e de formação óssea, respectivamente. Os níveis de P1NP foram significativamente 
reduzidos em ambas as doses em comparação com os animais doentes não tratados e o CTX-I, apesar 
de não ter resultados significativos, segue a mesma tendência. Mais ainda, a quantificação no soro do 
TRAcP 5b, marcador preditivo do número de osteoclastos totais, levou a concluir que o celastrol diminui 
o número destas células, tal como observado na análise histopatológica e por imunohistoquímica. 
Os animais foram pesados ao longo do período experimental de forma a averiguar uma possível 
redução do peso corporal provocada pela administração do composto. Os ratos administrados com 5 
μg/g/dia de celastrol não apresentaram redução de peso porém, o grupo que recebeu a dose mais alta do 
composto (7.5 μg/g/dia) sofreu uma diminuição no peso significativa no dia 11 e 13 em comparação ao 
4º e ao 7º da experiência. A redução de 20% do peso em dois animais neste grupo comparativamente ao 
dia 4 provocou a sua eutanásia antecipada. Conduto, é de salientar que não existiram diferenças 
significativas no peso dos animais deste grupo nos dias em que receberam o tratamento. A avaliação dos 
biomarcadores de toxicidade no soro dos animais mostrou que o celastrol não provoca toxicidade nos 
rins e no fígado. Contudo, o enzima lactato desidrogenase (marcador de dano celular), aumentou 
significativamente nos animais tratados com 7.5 μg/g/dia de celastrol em comparação com os outros 
grupos e o enzima creatina cinase (marcador de dano muscular/cardíaco) revelou uma tendência a 
aumentar nos grupos tratados com celastrol em comparação aos ratos saudáveis. A análise ao marcador 
pro-ANP descartou efeitos adversos do celastrol no miocárdio. Por fim, foi ainda estudada a 
percentagem de leucócitos no sangue no fim do estudo. Nenhum dos grupos tratados com celastrol teve 
efeitos tóxicos nos leucócitos. 
Os resultados sugerem que o celastrol administrado oralmente a 5 e 7.5 μg/g/dia é eficaz a 
diminuir a inflamação assim como a reduzir as erosões osseas. No entanto, os efeitos tóxicos 
significativos observados no grupo tratado com celastrol a 7.5 μg/g/dia exclui possíveis usos do 
composto em ratos Wistar acima desta dose. A outra dose utilizada neste estudo (5 μg/g/dia) está a ser 
considerada para futuros estudos pré-clinicos mais detalhados. 
 
 
Palavras-chave: Artrite reumatóide, celastrol, modelo de artrite induzida por adjuvante em rato, 
administração oral, dosagem. 
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INTRODUCTION 
 
Rheumatoid arthritis 
Definition 
 
Rheumatoid arthritis (RA) is a chronic and progressive auto-immune disease which is mainly 
characterized by polyarticular inflammation with consequent bone and cartilage destruction. It is 
associated with systemic inflammation which often results in disorders of multiple organ systems. The 
prevalence of RA varies between 0.3 and 1.1% [1]. 
Despite being a heterogeneous disease, common symptoms include tender, warm and swollen 
joints, morning stiffness, edema and weight loss. Smaller joints tend to be affected in the early phase 
and, as the disease progresses, symptoms often spread to the wrists, knees, ankles, elbows, hips and 
shoulders [2]. Over time, RA can cause the deformation of joints, secondary osteoporosis and other 
associated comorbidities which decrease life expectancy [3].  
Although it is a complex and yet uncompletely understood disease, the last years’ advances have 
allowed clinicians and researchers to establish new targets in order to develop more effective therapies. 
The current treatment methods, which reflect this progress, require an aggressive therapy to start soon 
after diagnosis and need to be tailored according to the disease activity of each patient, in pursuit of 
clinical remission [4]. The classification criteria set, which is used to define RA, is based on 2010 
American College of Rheumatology/European League Against Rheumatism (2010 ACR/EULAR) and 
takes into consideration the number of swelled joints, presence of Rheumatoid Factor (RF) and anti-
citrullinated protein antibodies (ACPA), levels of c-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR), and the duration of symptoms [5]. 
 
Etiology 
 
RA results from a complex set of key events that drive a severe autoimmune attack against 
endogenous tissues. Substantial evidences have been proving that the disease initiates with a minor event 
in a genetically susceptible individual, such as a specific environmental exposure or a stochastic episode, 
triggering a positive-feedback cycle that eventually leads to persistent immunopathology [6, 7]. The 
reactivity against a self-antigen is variable between RA patients however, 70-80% of the patients are 
seropositive for ACPAs, autoantibodies that recognize peptides containing citrulline (aminoacid 
generated by a post-translational modification) or for RF, autoantibodies that bind to Fc domain of 
immunoglobulins from IgG class [8]. Citrullination is a normal intracellular physiologic process [9], 
however, inflammatory conditions may cause the release of citrullinated peptides to the 
microenvironment enabling their contact with the immune system and eliciting the production of 
autoantibodies [10]. The main targets of ACPA in the joint are citrullinated forms of fibrinogen, α-
enolase, vimentin and fibronectin [11-14]. Hence, the autoantibodies present in the serum potentiate the 
formation of immune complexes (ICs) that opsonized with complement system proteins recruit innate 
and adaptive immune cells [15]. In these cases the autoantibodies can be detected in patients’ serum up 
to 10 years before the onset of the disease [16] and are related with a more aggressive disease course 
and reduced rates of remission [17]. 
The presence of autoantibodies is strongly dependent on the genetic background of the patient 
[18, 19]. Some polymorphisms in human leukocyte antigen (HLA)-DRB1 gene namely in alleles HLA-
DRB1*04, *01 and *10 imply a functional alteration in major histocompatibility complex (MHC) class 
II, making the molecule capable of accommodate citrulline residues and present them to T cells, which 
in turn incite B cells to produce more autoantibodies [20, 21]. 
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Certain polymorphisms in alleles related with nuclear factor κB (NF-κB) dependent signaling, 
such as tumor necrosis factor receptor-associated factor 1 (TRAF1/C5) [22], or with T cell stimulation, 
activation and functional differentiation, such as protein tyrosine phosphatase non-receptor type 22 
(PTPN22) [23] and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) [24], can also be associated 
to a high risk of developing RA. 
From all the environmental risks for RA, smoking is the strongest factor [6]. Its attributable risk 
is 20% for all RA and 35% for ACPA+ RA [25]. Other factors also associated with increased risk for 
RA include periodontitis [26], air pollution [27] and silica [28]. 
 
Pathophysiology  
 
A joint is a structure where two or more bones connect with each other. Cartilage covers the end 
of each bone and is responsible for lubrication, articulation, loading and resistance of the bone [29-31]. 
Its properties are consequence of the macromolecular extracellular matrix (ECM) that are synthetized 
and maintained by cartilage cells, the chondrocytes [32]. Surrounding the cartilage is the synovia 
constituted by synovial membrane (SM) which lines the cavities of joints, and synovial fluid (SF), that 
lubricates the articulating surfaces [33]. A healthy SM is a relatively acellular structure consisting of a 
distinct intimal lining layer and a sublining layer. The intimal lining layer is composed by synoviocytes 
identified as being from macrophage or fibroblast lineage. The sublining layer contains blood vessels, 
adipocytes and fibroblasts, with few lymphocytes and macrophages [34]. In individuals with RA the 
synovia is invaded with leukocytes, proinflammatory cytokines, chemokines, metalloproteases (MMPs) 
and prostaglandins that drive inflammation and bone and cartilage resorption [35-38]. 
The migration of leukocytes from peripheral blood to the joints in RA is ensured by the massive 
amount of chemokines and adhesion molecules produced by vascular endothelium and synovial lining 
layer cells as a consequence of disease [39]. In fact, there are evidences that the cytokine-rich 
environment that occurs in RA induces leukocytes to acquire novel chemokine responsiveness 
prompting their migration to the joints [40]. For instance, blood neutrophils from patients with early RA 
express de novo CCR2, a receptor expressed in monocytes and lymphocytes, not in neutrophils in the 
physiologic state. This alteration is important for the further migration of these cells to the inflamed 
tissue [41]. Moreover, angiogenesis is also an early and critical event in RA and results in an expanded 
endothelial surface, which may promote more intense inflammatory cell ingress into the synovia [42].  
Neutrophils are the most abundant and the first leukocytes to migrate to the SF [43]. Indeed, 
interleukin (IL)-8, a potent chemotactic agent for neutrophils is significantly increased RA patients’ SF 
in comparison with peripheral blood [44]. The inflamed synovia induces an alteration of neutrophil’s 
activation, recruitment and apoptosis [45-47] promoting the production of inflammatory cytokines [48] 
and the release of high concentrations of reactive oxygen species (ROS) as well as cytotoxic agents that 
contribute to the cartilage degradation [49].  
The inflammatory character of RA is also sustained by macrophages (Mφ). Besides the capacity 
of presenting autoantigens to T cells, Mφ have the ability to differentiate into osteoclasts (bone resorbing 
cells), which further contribute to bone damage [50]. Moreover, this type of cells overexpresses a 
number of cytokines that drive and intensify inflammation. Among them are TNF, IL-1β and IL-6 whose 
levels are concomitantly increased in RA patients’ serum  [51-53] and in SF [54]. TNF and IL-1 
potentiate monocyte activation, adhesion molecules expression by endothelial cells [55] and stimulate 
chondrocyte and fibroblast-like synoviocytes (FLS) to degrade cartilage [55, 56]. TNF also inhibits 
functions of regulatory T cells (Treg) [57], induces effector T cells resistance to Treg-mediated 
suppression [58] and induce pain and fever [59]. IL-6 has been shown to increase to the production of 
autoantibodies by acting on plasmablasts [60]. All these cytokines are also major players dysregulating 
bone imbalance, enhancing bone resorption [61], as discussed below. In addition, Mφ also secrete IL-
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23 and IL-12 which are responsible for T helper 17 cells (TH17) and TH1 polarization, respectively [62, 
63]. 
Autoantigen recognition by T cells ensures the self-perpetuation of the disease as the mutual 
stimulation between T and B cells triggers autoantibodies production [64]. In fact, CD4+ T cell depletion 
using specific antibodies suppresses autoantibody production and reduces disease severity in collagen- 
or antigen-induced arthritis models in rodents [65, 66]. TH17, the most abundant subpopulation of T 
cells present in the synovia [67], secrete a huge amount of IL-17 which is responsible for FLS, 
monocytes and neutrophils activation [68] as well as osteoclastic bone resorption [67, 69]. Synovial B 
cells are mainly localized in T and B aggregates, and are supported by the expression of factors that 
include B-lymphocyte stimulator (BlyS) and proliferation-inducing ligand (APRIL) which are highly 
expressed in the synovia [70]. 
As RA becomes chronic, increased synovial cell proliferation leads to pannus formation. This 
hypertrophic and hyperplastic synovial tissue is highly invasive and is responsible for bone and cartilage 
erosions [71]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I - Representative scheme illustrating immune cells and cytokine networks in rheumatoid 
joints. In RA, the inflammatory process leads to a cellular infiltration of the synovial membrane and 
synovial fluid, with consequent pannus formation, cartilage and bone destruction. Immune cells are 
responsible for the secretion of high amounts of several cytokines that amplify inflammation by the 
recruitment and activation of immune cells. ACPA – Anti-citrullinated protein antibodies, APRIL – A 
proliferation-inducing ligand, BLyS – B-lymphocyte stimulator, IFNγ – Interferon gamma, IL – 
Interleukin, IL-6R – IL-6 receptor, MCP-1 – Monocyte chemotactic protein-1, MHC – Major 
histocompatibility complex, MMP – Metalloproteinase, RANKL – Receptor activator of nuclear factor 
ligand, RF – Rheumatoid factor, TCR – T cell receptor, TGFβ – Transforming growth factor beta, Th – 
T helper, TNF – Tumor necrosis factor. Adapted from [46].  
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Bone remodeling 
 
Bone is a rigid but dynamic tissue composed by an organic matrix, mostly formed by fibers of 
collagen type I [72] and by a mineral phase of inorganic components, mainly hydroxyapatite [73]. The 
composition and organization of the bone matrix gives this tissue special mechanical properties such as 
stiffness, ductility, rigidity and tensile strength. In order to maintain its structural integrity, bone is 
continuously shaped and repaired in a process called bone remodeling [74, 75].  
Physiological bone remodeling is orchestrated by two main cell types with opposing functions: 
osteoblasts, which form new bone, and osteoclasts, which resorb damaged or old bone. Osteoblasts are 
cells of mesenchymal origin that secrete bone-matrix proteins such as osteocalcin, a protein that is 
responsible for the calcium binding in bone matrix, therefore being considered as a specific marker of 
osteoblastic function [76]. They can transform into osteocytes or in bone lining cells. Osteocytes are 
osteoblasts trapped in the bone matrix. These type of cells produce signals to regulate osteoclasts and 
osteoblasts as a consequence of bone loading [77]. Bone lining cells are flat cells that cover available 
bone surfaces and act as a barrier that separates the bone from interstitial fluids and controls the mineral 
homeostasis of the bone [78]. On the other hand, osteoclasts are cells from monocyte/macrophage 
lineage responsible for the acidic decalcification and proteolytic degradation of the bone matrix [79]. 
The remodeling cycle begins with an initiation phase that includes the recruitment of Mφ to the 
resorption site. This is followed by their fusion and attachment of the subsequent multinucleated cell to 
the bone surface. The mature and multinucleated osteoclast is activated by signals which lead to 
initiation of bone resorption [80]. 
Osteoclasts differentiation, survival and activity is mediated by macrophage colony-stimulating 
factor (M-CSF) and receptor activator of nuclear factor NF-kB ligand (RANKL) [81]. Both mediators 
induce the transcription factor nuclear factor of activated T cells-1 (NFATc1), responsible for the up-
regulation of various genes related with osteoclast adhesion, migration, acidification, degradation of 
inorganic and organic bone matrix [82, 83]. After RANKL-stimulation osteoclasts express tartrate-
resistant acid phosphatase 5b (TRAcP 5b), an enzyme  released into the serum that is considered a 
marker of osteoclasts number and, upon further stimulation, cathepsin K, an enzyme responsible for 
collagen type I cleavage, considered as a marker of osteoclastic resorption [84]. RANKL is tightly 
regulated by its decoy receptor, osteoprotegerin (OPG), both produced by osteoblasts. OPG prevents the 
interaction of RANKL with RANK, receptor on the surface of osteoclasts. Thus, the RANKL/OPG 
system constitutes an important indicator predicting either excessive bone resorption or bone formation 
[85].  
The huge amount of proinflammatory cytokines present in the joint dysregulate osteoclastogenic 
balance [86-91]. Special attention should be paid to IL-1 that mediates the osteoclastogenic effect of 
TNF-α and stimulates the differentiation of osteoclasts precursors [86] and to TNF that promotes 
RANKL production [92], synergizes with RANKL to amplify osteoclastogenesis [93, 94] to intensify 
osteoclastic resorption [95]. 
There are biomarkers that reliably detect ongoing bone turnover and are useful to monitoring not 
only disease progress but also the efficacy of a treatment. Some of them are used to identify severity 
and risk of progression of joint damage in RA and other diseases such as osteoporosis [96-99]. They are 
also used in several animal models of arthritis [100, 101]. N-terminal propeptide of type I collagen 
(P1NP) is a peptide derived from the N-terminal of type I procollagen that is enzymatically cleaved at 
the moment of bone formation and liberated into the circulation, acting as a marker of bone formation. 
C-terminal telopeptide of collagen type I (CTX-I) is a portion of the C-terminal part of collagen type I 
that is cleaved by cathepsin K and is released into the circulation at the time of bone resorption, acting 
as a marker of bone resorption [102]. 
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Treatment strategies 
 
Since RA is still an incurable disease, current treatment strategies are focused on halt the 
inflammation, prevent joint damage and maintain the patient’s quality of life and ability to function in 
pursuit of clinical remission [4]. 
There are three major classes of drugs commonly used in the treatment of RA: non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids and disease modifying anti-rheumatic drugs 
(DMARDs). 
NSAIDs are effective agents decreasing pain and suppressing minor inflammation. However, 
NSAIDs do not modify the disease course nor reduce acute-phase reactants being only used as first-line 
agents for the symptomatic relief [103]. 
Glucocorticoids are useful to control symptoms, to preserve function until DMARDs start to exert 
their effects and also to treat flares of disease while the patient is receiving other treatments [104]. 
Nonetheless, significant side effects of glucocorticoids require the use of the lowest possible dose for 
the shortest period of time [105]. 
DMARDs are used with the aim of promoting a benefic long-term effect since they can modify 
the disease course improving inflammation and joint damage [106, 107]. This class of drugs can be 
divided in two groups: the conventional and the biologic DMARDs. Among conventional DMARDs, 
methotrexate (MTX) is the most frequently used due to its favorable efficacy/toxicity ratio [108, 109]. 
In addition, MTX can be used as co-treatment in patients treated with other conventional or biologic 
DMARD. 
Besides the good outcomes of conventional DMARDs, biologic agents target strategic molecules 
in RA network. Biologic DMARDs are often reserved for patients who have not completely responded 
or cannot tolerate conventional DMARDs in doses large enough to control inflammation [110, 111]. 
Several biologic DMARDs are being commercialized and others are being tested in clinical trials. 
Currently, there are five available anti-TNF agents such as infliximab, etanercept, adalimumab, 
certolizumab pegol and golimumab [112]. Also included in the group of biologic DMARDs are T cell 
co-stimulation inhibitor abatacept, the anti-B cell agent rituximab, the IL6R-blocking monoclonal 
antibody tocilizumab and the IL-1 inhibitor anakinra [113].  
Therapy with DMARDs should be started as early as possible after the diagnosis of RA [114]. It 
is recommended the use of MTX as the first-line treatment in patients with active RA, unless 
contraindicated, and it may be accompanied with low-dose of glucocorticoids [115, 116]. Combination 
therapies with two or more DMARDs are more effective than monotherapy however, adverse effects 
may also be greater [117]. If RA is not well controlled with a conventional DMARD, a biologic 
DMARD should be initiated simultaneously. Several data suggest that biologic therapy combination are 
not recommended due to a higher rate of adverse events and/or lack of additive efﬁcacy [118, 119]. 
Despite the clinical efficacy of these therapies, around 30% of patients discontinue treatment due 
to a weak clinical response or to adverse effects [120-122]. Furthermore, the limited availability of 
biologics in developing countries and its relatively high cost impair many RA patients to access  these 
therapies [123]. As an attempt to find a more reliable therapy, increasing number of agents derived from 
natural sources have drawn increasing attention in the last years. These type of compounds are generally 
less toxic and better tolerated than many of the aforementioned conventional drugs [124].   
 
Celastrol 
Celastrol, a pentacyclic-triterpene, is a bioactive component of the medicinal plant Trypterigium 
wilfordii Hook F., also known as Thunder God Vine (TGV). It has been widely used in Chinese medicine 
to treat auto-immune disorders and cancer [125]. Over the past decades, due to its remarkable anti-
6 
 
oxidant, anti-inflammatory and anti-cancer properties, celastrol has been considered a promising 
candidate for drug development. In fact, its effects have been demonstrated in animal models of 
Alzheimer disease [126], asthma [127], systemic lupus erythematosus [128] and RA [129-131]. Those 
experiments and others have disclosed some of the key molecular targets of celastrol. It has been shown 
that the compound has the ability to modulate the expression of several pro-inflammatory cytokines 
[132], inhibit inducible nitric oxide synthase (iNOS) [133], adhesion molecules in endothelial cells 
[134], proteasome activity [135], topoisomerase II [136], potassium channels [137] and heat shock 
response [138]. Celastrol is also known to inhibit the proliferation, angiogenesis and metastasis of a 
variety of tumor cells [135, 139-141].  
Interestingly, celastrol has been known for its remarkable action in the context of RA. Yu Y. et 
al [142] treated purified neutrophils from healthy donors and RA patients with celastrol and discovered 
that the compound inhibited neutrophils’ oxidative burst and extracellular traps formation. Zengtao Xu 
and colleagues [143] revealed that celastrol is capable of counteract FLS hyperplasia inducing its DNA 
damage, cell cycle arrest as well as apoptosis and Li GC. et al [144] showed that the compound 
suppressed hypoxia-induced human FLS migration and invasion by inhibiting C-X-C chemokine 
receptor type 4 (CXCR4) pathway. Furthermore, other groups have reported that celastrol significantly 
decreased the levels of the pro-inflammatory cytokines IL-17, IL-6, TNF, IL-1β and IL-18 in vitro [145] 
and reduces the expression of phosphorylated signal transducer and activator of transcription 3 
(pSTAT3), an important transcription factor in IL-17 production [129].  
An in vitro drug screening performed by our group to select compounds that simultaneously inhibit IL-
1β and TNF secretion, two major players in RA physiophatology, identified celastrol as a potent 
inhibitor of those cytokines and also of NF-κB and caspase-1 secretion [131]. We further tested the anti-
inflammatory effects of celastrol using an adjuvant-induced rat model of arthritis (AIA) and reported 
that this compound was able to significantly suppress inflammatory symptoms including cell infiltration 
and proliferation in arthritic joints in an early and late stage of disease progression as well as reduce 
CD68+ synovial macrophages, cells that are reduced in adequated therapeutic responses for RA [146]. 
Supporting our own results, Venkatesha et al [147], using the same rat model, documented a significant 
decrease in several chemokines responsible for cell recruitment to the inflammation site in celastrol-
treated rats in comparison with arthritic-untreated rats. They also showed that celastrol significantly 
reduced the levels of anti-cyclic citrullinated peptide (CCP) antibodies, had an inhibitory effect on 
metalloproteinase (MMP)-9 and decreased Th17/Treg cell ratio in the joints [148]. 
There are some randomised controlled trials to evaluate the pharmacological effects and clinical 
toxicity of TGV. A study have reported that TGV extracts (TE) significantly improved the overall 
assessments of adult RA patients when compared with patients under placebo treatment [149].  
Moreover, there are some heterogeneities in literature regarding the comparison between TE and 
DMARDs, however a recent study with 207 patients with active RA showed that the combination 
therapy of TGV and MTX led to a 1.6 fold increase in american college of rheumatology 50% of 
response rate (ACR50) than MTX monotherapy, further suggesting the beneficial effect of TGV in the 
treatment of RA [150]. From the studies made so far it was reported some adverse effects that should 
not be overlooked, including mild to moderate gastrointestinal events and amenorrhea in humans [149, 
151] and hepato- and nephrotoxicity in mice [152]. However, these toxic events were described as a 
consequence of the administration of TE, a heterogeneous product that exhibit a high degree of 
variability in its composition. Thus, the use of a pure compound, as celastrol, is more appealing since it 
is easier to monitor its quality and concentration. Up to now there are few reports regarding adverse 
effects of pure celastrol. Jakob Hansen et al [153] have stated that celastrol could reduce lymphoblastoid 
viability in a dose-dependent way  and Sifeng Wang et al [154] have showed that the compound affected 
the normal development of zebrafish embryo. However, our previous studies conducted in AIA rats, a 
model of arthritis capable of predict toxicity in humans [155], have proved that celastrol has not short-
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term toxicity when intraperitoneally administered at 1µg/g/day [146]. In addition, more complete studies 
regarding long-term toxicity induced by celastrol are being peformed by our group.  
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AIMS 
 
RA is a chronic auto-immune inflammatory disease with irreversible damage in cartilage and 
bone. Early diagnosis and advances in molecular biology have tailored the current therapy to a complete 
and long-lasting remission but only partial remission is achieved and frequent relapses as well as safety 
issues are common. Thus, the development of a therapy based on a small molecule, allowing oral 
administration, with low production costs, effective and safe remains an unmet medical need.  
Previous data from our group have shown in the AIA rat model that celastrol, a bioactive 
compound from TGV, when administrated intraperitoneally, possesses significant anti-inflammatory 
and anti-proliferative properties in the early and established phase of arthritis, without adverse effects 
[146]. However, it still remains to prove its efficacy when orally administered. Moreover, the lack of 
significant toxicity reports led us to evaluate the toxicological profile of celastrol in this route of 
administration. Hence, the main aim of this project was to evaluate the anti-inflammatory and bone 
protective properties of celastrol when orally administered as well as analyze its safety profile in the 
same administration route. This study intent to provide a rationale for setting dose levels for further 
preclinical studies. 
 
Specific aims: 
 
Aim 1 – To evaluate ethanol as a possible vehicle for the oral administration of celastrol in the 
AIA rat model; 
Aim 2 – To assess the anti-inflammatory properties of celastrol when orally administered in the 
AIA rat model in vivo and in joint articular tissues; 
Aim 3 - To investigate the effect of celastrol when orally administered in bone turnover markers 
as well as in a bone resorption marker; 
 
Aim 4 - To analyse toxic effects caused by oral administration of celastrol. 
 
 
 
  
* 
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MATERIALS AND METHODS 
Animal model and experimental design 
Eight-week-old Wistar adjuvant-induced arthritis (AIA) female rats were obtained from Charles 
River Laboratories International (Massachusetts, USA) weighing 230-250 g. Animals were housed 
under specific pathogen free (SPF) conditions at 22°C with 12-hour light/12-hour dark cycles and food 
and water were provided ad libitum. Before the initiation of the studies, animals were allowed to 
acclimatize in the animal facility for 5 days. The animals were euthanized when presenting deformities 
and functional impairment in more than 2 paws or more than 20% of body weight loss. All experiments 
were approved by the Animal User and Ethical Committees at the Instituto de Medicina Molecular, 
according to the Portuguese law and the European recommendations. 
The induction of the AIA rat model was performed by Charles River Laboratories and is detailed 
reported elsewhere [156]. Briefly, Wistar rats were inoculated with an intradermal injection at the right 
hind paw of heat-killed Mycobacterium tuberculosis suspended in paraffin oil. The preclinical phase of 
the model extends from the day of arthritogen administration until the day of clinically visible arthritis 
onset, nearly the 9th day. The next ten days are characterized by the acute clinical phase of the disease 
when the body weight loss, progressive inflammation and skeletal erosions are more intense. This phase 
is are followed by a period of remission that implies the end of the study [157]. The similarity between 
the AIA rat model and human RA as well as greater disease severity and progression in comparison with 
other arthritic models makes this model suitable for preclinical studies and extensively used by the 
pharmaceutical industry [155].  
Celastrol (Sigma, Missouri, USA) (purity ≥ 98 %) was dissolved in ethanol 100% at a 
concentration of 10mg/mL. Subsequently the stock solution was diluted using polyethylenglycol 400 
(PEG400) (Sigma, Missouri, USA) for intragastric administration in animals.  
To study the anti-arthritic properties and possible side effects of celastrol when orally 
administered, rats were randomly assigned to four experimental groups: two groups of AIA rats were 
treated with celastrol, daily by gavage (intragastric delivery), at 5 or 7.5 µg/g body weight (N=6 each 
group) and a group of AIA untreated rats (N=15) as well as a group of healthy non-arthritic of female 
age-matched Wistar rats (N=8) received vehicle (ethanol 17% in PEG 400) or water by gavage, 
respectively. Treatment with celastrol was initiated 8 days after disease induction, following a 
therapeutic model [158], and was maintained until day 22, when animals were euthanized by CO2 
narcosis. The need for daily administrations is supported by Zhang J. et al who showed that the half-life 
of pure celastrol is approximately 10 hours [159]. In order to evaluate ethanol as a vehicle, a group of 
AIA rats was submitted to oral administration of ethanol 17% (Arthritic EtOH+) (N=15) and compared 
with a group of arthtiric animals who did not receive ethanol (Arthritic EtOH-) (N=5). The percentage 
of ethanol used in this assessment corresponded to the volume of ethanol administered in the highest 
dose of celastrol (7.5 µg/g/day) preparation. 
Ankle swelling, body weight and inflammatory score were measured throughout the experiment. 
Inflammatory signs were evaluated by counting the score of each joint in a scale of 0–3 (0 — absence 
of inflammatory signs; 1 — erythema; 2 — erythema and swelling; 3 — deformities and functional 
impairment). The total inflammatory score of each animal was defined as the sum of the partial scores 
of each affected joint [160]. At the time of sacrifice the blood was collected from each animal. Serum 
and plasma were obtained and stored at -80ºC. Left hind paws as well as internal organs such as the 
liver, spleen, lung, kidney, heart and thymus were also collected and fixed in 10% formalin solution for 
further analysis. 
. 
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Histopathological and immunohistochemical evaluation of the left hind paws 
Paw samples, after being fixed with 10% neutral buffered formalin solution and dehydrated with 
increasing ethanol concentrations (70%, 96% and 100%), were also decalcified in 10% formic acid. 
After embedded in paraffin, the samples were serially sectioned at a thickness of 5 μm and mounted on 
microscope slides. An hematoxylin and eosin staining was applied for morphological examination. Data 
regarding the synovial lining layer number was scored from 0-3 (0- fewer than 3 layers; 1- three to four 
layers; 2- five to six layers; 3- more than six layers) [161]. The sublining layer cell infiltration was 
scored from 0-4 (0- none; 1-lymphoid cell infiltration; 2- lymphoid aggregates; 3- lymphoid follicles; 
4- lymphoid follicles with germinal center formation) [161]. Bone erosion was scored from 0-4 (0- no 
erosions; 1- minimal; 2- mild; 3- moderate; 4- severe) [160].  Global severity of the disease was scored 
from 0-3 (0- no sign of disease/inflammation; 1- mild; 2- moderate; 3- severe). Paw sections were also 
used for immunohistochemical staining with CD68, Ki67, osteocalcin (markers of macrophages and 
fibroblasts, proliferation and bone formation, respectively) (Abcam, Cambridge, UK) and cathepsin K 
(marker of bone resorption) (Biorbyt, Cambridge, UK) antibodies. Tissue sections were incubated with 
the primary antibody and with EnVision+ (Dako, Glostrup, Denmark) and color was developed in 
solution containing diaminobenzadine-tetrahydrochloride (Sigma, Missouri, USA). Slides were 
counterstained with hematoxylin and mounted. Immunohistochemical evaluation of rat joints was 
performed using a semi-quantitative score of 0–4 (0- no staining; 1– 0–25% staining; 2– 25–50% 
staining; 3– 50–75% staining; 4- more than 75% staining) [131]. All images were acquired using a Leica 
DM2500 (Leica microsystems, Wetzlar, Germany) microscope equipped with a CCD color camera. 
 
Quantification of the systemic markers of bone turnover and resorption 
Bone turnover markers CTX-I and P1NP (Immunodiagnostic System, Boldon, UK) as well as 
bone resorption marker TRAcP5b (Immunodiagnostic System, Boldon, UK) were quantified in serum 
samples using specific rat enzyme linked immunosorbent assay (ELISA) kits according to the provider's 
recommendations. Standard curves for each marker were generated by using reference concentrations 
supplied by the manufacturer. Samples were analyzed using a plate reader Infinite M200 (Tecan, 
Mannedorf, Switzerland). 
 
Toxicological evaluation  
Organs samples were fixed immediately in 10% neutral buffered formalin solution and then 
dehydrated with increasing ethanol concentrations (70%, 96% and 100%). Samples were next embedded 
in paraffin, sectioned and stained with hematoxylin and eosin. Tissue histopathological changes were 
examined by a pathologist blinded to the experimental groups (data not shown). All images were 
acquired using a Leica DM 2500 microscope (Leica microsystems, Wetzlar, Germany). Moreover, 
blood toxicological parameters, such as creatine kinase, urea, alanine transaminase, lactate 
dehydrogenase (BioAssay Systems, California, USA), measured in serum, and cardiac toxicological 
mediator pro-ANP (Biomedica, Wien, Austria), measured in plasma, were performed by ELISA 
technique according to the manufacturer’s instructions. Samples were analyzed using a plate reader 
Infinite M200 (Tecan, Mannedorf, Switzerland). Blood samples were used to obtain white blood cell 
count (VetinLab, Lisbon, Portugal). 
Statistical analysis 
Data was analysed using GraphPad Prism 5 Software (GraphPad, California, USA). The 
normality distribution was assessed by D’Agostino and Pearson omnibus normality test. For populations 
that did not follow a Gaussian distribution it was performed nonparametric Mann-Whitney tests for 
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comparisons between 2 independent groups. Data are represented as median with interquartile range. 
Differences were considered statistically significant for p<0.05.  
 
 
.  
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RESULTS 
 
1. Evaluation of ethanol as a vehicle for the oral administration of celastrol in the AIA rat 
model 
 
Celastrol’s poor water solubility implies the selection of an organic solvent capable of solubilize 
the compound. Dimethylsulfoxide (DMSO), one of the recommended solvents for celastrol, presents 
intragastric toxicity when orally administered [162]. Hence, our group has considered the use of another 
recommended solvent for the compound, ethanol.  To examine the effect of ethanol as a suitable vehicle 
in this set-up, a group of AIA rats received ethanol 17% in PEG400 by gavage starting 8 days after 
disease induction until day 22 (arthritic EtOH+). A group of AIA rats that did not receive ethanol 
(arthritic EtOH-) and healthy rats were used as controls for comparison. There were no significant 
differences in inflammatory manifestations of the disease, evaluated during the treatment period 
(appendix 1), between the two arthritic groups. Twenty-two days after disease induction, both arthritic 
groups showed a significant increase in the inflammatory score (p=0.0001 and p=0.0019 in arthritic 
EtOH+ and arthritic EtOH- groups vs healthy controls, respectively, shown in Fig 1.1A) and ankle 
swelling (p=0.0004 and p=0.0032 in arthritic EtOH+ and arthritic EtOH- groups vs healthy controls, 
respectively, shown in Fig 1.1B) comparing with the healthy controls.  Moreover, we have not found 
significant differences between the arthritic groups revealing that ethanol does not have an impact on 
disease activity.   
  Histopathological examination of left hind paw sections also validated the above mentioned data 
(illustrative images can be observed in Fig 1.1C). We have also assessed global disease severity score 
as an indicator of the impact of arthritis on joint articular tissues. The results, depicted in Fig 1.1D, 
showed that both arthritic groups have a significant increase in global disease severity in comparison 
with healthy controls (p=0.0001 and p=0.0019 in arthritic EtOH+ and arthritic EtOH- groups vs healthy 
controls, respectively), with no significant differences between them.  
In order to evaluate potential side effects of intragastric administration of ethanol in AIA rats, 
body weight was measured during the experiment (Apprendix 2). Arthritic animals weighted less on day 
22 than healthy rats (p=0.0016 and p=0.0043 in arthritic EtOH+ and arthritic EtOH- groups vs healthy 
controls, respectively, as shown in Fig 1.1E) as consequence of arthritis. Importantly, comparing the 
two arthritic groups there was no significant difference.  
The similarity in arthritis condition and the absence of differences in body weight, an indicator of 
toxicity, between the two arthritic groups, validate the further use of ethanol as a vehicle for oral 
administration of celastrol in AIA rats. 
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Figure 1.1 - Evaluation of ethanol as a vehicle for the oral administration of celastrol in the AIA rat 
model. At the end of the experiment arthritic EtOH+ and arthritic EtOH- groups did not show 
differences in inflammatory score (A) and in ankle swelling (B). The similarity between the two arthritic 
groups in disease condition was validated by the histological representation of the joints (C) and global 
severity score (D). Ethanol did not provoke a reduction of body weight (E). Erosions are identified with 
“E” and synovial membrane with “S”. Magnifications of 50× and 100×. Bars: 200 μm. Differences 
were considered statistically significant for p-values<0.05 (*). Data are expressed as Median with 
interquartile range. Healthy N=8, arthritic EtOH+ N=15 and arthritic EtOH- N=5. 
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2. In vivo assessment of the anti-inflammatory properties of celastrol in the AIA rat model 
Once validated the use of ethanol as a suitable solvent for celastrol for this set-up, our group 
focused on evaluating orally administered celastrol, in two different doses, using ethanol 17% in 
PEG400 as a vehicle for comparison. 
AIA rats were treated with 5 or 7.5 µg/g/day of celastrol, starting 8 days after arthritis induction 
(therapeutic model of administration), until day 22, when the model starts remission. A group of healthy 
and AIA control rats (arthritic-untreated) received water and vehicle by gavage, respectively. Figure 
2.1A illustrates the variation in inflammatory score between all the experimental groups throughout the 
disease course. 
By the fourth day of disease induction, all AIA animals already presented signs of arthritis. In 
arthritic-untreated animals, the inflammatory manifestations sharply increased from day 10th onwards. 
Since the first day of treatment, signs of inflammation in both celastrol-treated groups were attenuated. 
At day 15, inflammatory signs in celastrol at 5 μg/g/day treated group were mantained and the group 
treated with the highest dose of the compound (7.5 µg/g/day) even showed a tendency to decrease their 
inflammatory score. Importantly, the inflammatory signs of arthritis in both celastrol-treated groups 
were already significantly reduced in comparison with the arthritic-untreated group since day 11 
(p=0.0449 in 7.5μg/g/day celastrol-treated group vs arthritic-untreated group) or since day 14 (p=0.0096 
in 5μg/g/day celastrol-treated group vs arthritic-untreated group).  
By the end of the study, both doses of celastrol were able to significantly decrease the 
inflammatory score (p=0.0039 and p=0.0032 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs 
arthritic-untreated group, respectively, shown in Fig 2.1B) and ankle swelling (p=0.0032 and p=0.0073 
in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs arthritic-untreated group, respectively, shown 
in Fig 2.1C). 
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Figure 2.1 - In vivo evaluation of celastrol’s anti-inflammatory properties in the AIA rat model.  (A) 
Celastrol is able to suppress inflammation throughout time. Celastrol in both doses was able to halt the 
inflammatory score whereas the arthritic-untreated animals kept increasing the inflammatory score. 
The arrow indicates the beginning of the treatment, 8 days after disease induction. (B) The inflammatory 
score and (C) ankle swelling of celastrol-treated animals was maintained significantly decreased at the 
end of the experiment in comparison with arthritic-untreated animals. Data are expressed as Median 
with interquartile range. Differences were considered statistically significant for p-values<0.05 (*). 
Healthy N=8, arthritic-untreated N=15, celastrol at 5 μg/g/day treated group N=6, celastrol at 7.5 
μg/g/day treated group N=6. 
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3. Histopathologic evaluation of the left hind paw after treatment with celastrol 
The histopathologic evaluation of rats left hind paw sections was performed using a semi-
quantitative score as described in materials and methods section (illustrative images can be observed in 
Fig 3.1A)  
Synovial cell infiltration was significantly increased in arthritic-untreated animals when 
compared with healthy controls (p=0.0002, shown in Fig 3.1B). Celastrol was able to significantly 
decrease the infiltration into affected joints when compared with arthritic-untreated animals (p=0.0012 
and p=0.0008 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs arthritic-untreated group, 
respectively). Synovial cell proliferation was assessed by counting the number of the lining layers in 
SM. This parameter was also significantly increased in arthritic-untreated animals when compared with 
healthy controls (p=0.0005 in arthritic-untreated rats vs healthy controls, shown in Fig 3.1C). In contrast, 
celastrol-treated groups have significantly decreased cell proliferation comparing with the arthritic-
untreated animals (p=0.0084 and p=0.0070 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs 
arthritic-untreated group, respectively). In celastrol 7.5 µg/g/day group cell proliferation in the SM was 
even similar to healthy rats. Moreover, celastrol-treated groups have significantly reduced bone erosions 
(p=0.0059 and p=0.0031 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs arthritic- untreated 
group, respectively, shown in Fig 3.1D), parameter that were significantly higher in arthritic-untreated 
animals in comparison with healthy animals (p=0.0001 vs healthy rats). The group treated with the 
highest dose (7.5 µg/g/day ) has preserved bone structure similar to healthy animals. As an indicator of 
the impact of arthritis on joint articular tissues, we scored the global severity of the disease. Reflecting 
the previous observations, arthritic-untreated rats showed a higher disease severity (p=0.0001 arthritic-
untreated group vs healthy controls, shown in Fig 3.1E) but celastrol in both doses have halted that 
phenotype (p=0.0108 and p=0.0038 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs arthritic-
untreated group, respectively). 
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Figure 3.1 - Histopathological evaluation of paw joints after celastrol treatment. (A) Histological 
representation of paw joints. Celastrol has inhibited cellular infiltration (B), cellular proliferation (C) 
and prevented bone erosion occurrence (D), allowing an improvement in disease severity (E). Synovial 
membrane is identified with “S”. Magnifications of 50× and 100×. Bars: 200 μm. Differences were 
considered statistically significant for p-values<0.05 (*). Data are expressed as Median with 
interquartile range. Healthy N=8, arthritic-untreated N=15, celastrol at 5 μg/g/day treated group N=6, 
celastrol at 7.5 μg/g/day treated group N=6. 
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4. Immunohistochemical evaluation of paw articular joints after treatment with celastrol  
 
To further validate the histopathological results, we stained by immunohistochemistry the left 
hind paw sections for several markers and analyzed the results with a semi-quantitative score (illustrative 
images can be observed in Fig 4.1A) 
Ki67 is a protein expressed in proliferation cells which was used to detect proliferative cells in 
the synovia. Arthritic-untreated animals have showed a significantly higher score in this marker than 
healthy rats (p=0.0002, shown in Fig 4.1B). Celastrol significiantly reduced cellular proliferation 
(p=0.0048 and p=0.0015 in celastrol 5 µg/g/day and 7.5 µg/g/day treated groups vs arthritic untreated 
group, respectively).  
We also used CD68, a biomarker of clinical response (Fig 4.1C). Decreased numbers of 
macrophages CD68+ in the synovia predict an adequate drug response in RA. Arthritic-untreated rats 
have increased numbers of synovial CD68+ cells rats in comparison with healthy controls (p=0.0005). 
Notably, celastrol in both doses was able to significiantly reduce the number of CD68+ macrophages in 
the synovia (p=0.0211 and p=0.0127 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs arthritic-
untreated group, respectively). 
Furthermore, to locally address the effects of celastrol in bone formation and resorption cells, paw 
sections were stained for osteocalcin and cathepsin k, respectively. Osteocalcin, a marker of osteoblasts, 
was significantly increased in arthritic-untreated animals (p=0.0002, shown in Fig 4.1D) and completely 
restored to healthy levels in both celastrol-treated groups (p=0.0015 and p=0.0001 in 5 µg/g/day and 7.5 
µg/g/day celastrol-treated groups vs arthritic-untreated group, respectively). The same result was 
observed in cathepsin k, a marker of osteoclasts, (p=0.0051 in healthy controls vs arthritic-untreated 
group; p=0.0243 and p=0.0448 in 5 µg/g/day and 7.5 µg/g/day celastrol-treated groups vs arthritic-
untreated group, respectively, shown in Fig 4.1E). 
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Figure 4.1 - Immunohistochemical evaluation of paw joint sections after treatment with celastrol. (A) 
Representative immunohistochemical sections of rat joints for each biomarker. Arthritic-untreated 
animals have significantly increased levels of positive cells for all the markers. Celastrol treatment, in 
both treatment groups, decreased Ki67 positive cells in the synovial membrane (B) and CD68 positive 
macrophages (C). Both celastrol-treated groups decreased the number of osteoblasts (D) and 
osteoclasts (E) to healthy levels. Magnifications of 100× and 200×. Bars: 200 μm. Differences were 
considered statistically significant for p-values<0.05 (*). Data are expressed as Median with 
interquartile range. Healthy N=8, arthritic-untreated N=15, celastrol at 5 μg/g/day treated group N=6, 
celastrol at 7.5 μg/g/day treated group N=6. 
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5. Serum bone resorption and bone turnover markers measurement after treatment with 
celastrol 
Bone turnover markers, such as P1NP and CTX-I as well as bone resorption marker TRAcP 5b, 
were measured in animals’ serum by ELISA (Fig 5.1).  
High levels of the P1NP protein, a reliable marker to predict bone formation, were detected in the 
serum of arthritic-untreated rats when compared with healthy controls (p=0.0055, as shown in Fig 5.1A). 
These levels were decreased by celastrol in both doses as proved by the significant difference between 
the arthritic-untreated and both celastrol-treated animals (p=0.0201 and p=0.0475 in 5 µg/g/day and 7.5 
µg/g/day celastrol-treated groups vs arthritic-untreated group, respectively). Of note, celastrol in both 
doses was able to decrease P1NP to similar levels to healthy rats. 
Accordingly, arthritic-untreated animals have significantly higher levels of CTX-I, a marker of 
bone resorption, than healthy rats (p=0.0186, shown in Fig 5.1B). Both treatment groups showed a 
tendency towards a decrease in CTX-I, however it did not reached statistical significance. 
Moreover, both doses significantly decreased TRAcP 5b serum levels, a bone resorption enzyme 
produced by osteoclasts (p=0.0022 and p=0.0090 in 5 µg/g/day and 7.5/µg/g/day celastrol-treated 
groups vs arthritic-untreated group, respectively, shown in Fig 5.1C). 
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Figure 5.1 - Quantification of serum levels of bone resorption and bone turnover markers in AIA rats 
after celastrol treatment.  Celastrol was able to significantly decrease bone formation (A), showed a 
tendency to decrease bone resorption (B) and significantly reduced the number of osteoclasts (C). 
Differences were considered statistically significant for p-values<0.05 (*). Data are expressed as 
Median with interquartile range. Healthy N=8, arthritic-untreated N=15, celastrol at 5 μg/g/day treated 
group N=6, celastrol at 7.5 μg/g/day treated group N=6. 
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6. Celastrol safety profile analysis  
 
In order to assess possible side effects caused by oral administration of celastrol, rats’ body weight 
was measured during the experiment (Figure 6.1A). Arthritic-untreated animals already weighted 
significantly less on day 7 when compared with healthy rats (p=0.0142). This reduction was sustained 
throughout the experiment due to disease progression. Celastrol at 5 µg/g/day did not cause a significant 
reduction of body weight during the experiment course in comparison with the 4th, the first day of 
experiment and even with the 9th day, the first day after drug administration (appendix 3A). Animals 
treated with 7.5 µg/g/day of celastrol lost significantly more weight by day 11 and 13 when compared 
with the 4th day (p=0.0103 and p=0.0087 in day 11 and day 13 in comparison with day 4, respectively) 
and with the 7th day (p=0.0050 and p=0.0102 in day 11 and day 13 in comparison with day 4, 
respectively, shown in appendix 3B). However, this group did not show significant differences in body 
weight during de treatment period. The reduction of 20% of body weight experienced by two animals 
from this group at day 12 and 18 in comparison with day 4, implied their euthanasia due to human end-
point. After day 17 the group treated wth the highest dose of the compound (7.5 µg/g/day) started to 
gain wight. Of note, at the end of the experiment, both celastrol-treated groups had recovered body 
weight and, though not significantly, showed a tendency to increase their weight in comparison with 
arthric-untreated rats (Fig 6.1B). 
Tissue damage caused by celastrol was also evaluated by the quantification of serum biochemical 
markers. Urea and alanine transaminase have showed no significant differences between groups, as 
shown in Fig 6.1C and 6.1D, suggesting that celastrol have not caused kidney and liver toxicity, 
respectively. Nevertheless, lactate dehydrogenase, an enzyme that predicts cell/tissue damage, is 
significantly higher in celastrol 7.5 µg/g/day treated group in comparison with the other groups 
(p=0.0177, p=0.0062 and p=0.0317 in celastrol 7.5 µg/g/day treated group vs healthy, arthric-untreated 
and celastrol 5 µg/g/day treated groups respectively, shown in Fig 6.1E). In addition, creatine kinase, a 
maker of cardiac and muscle damage, is significantly increased in both celastrol-treated groups in 
comparison with healthy animals (p=0.0221 and p=0.0303 in celastrol 5 µg/g/day and 7.5 µg/g/day 
treated groups vs healthy group, respectively, shown in Fig 6.1F). Importantly, despite there were no 
significant differences between celastrol-treated and arthritic-untreated groups, there was a trend 
towards an increase in treated groups. In order to investigate cardiac dysfunction, Pro-ANP was also 
analysed, a molecule released into circulation as a consequence of the stretch of the myocyte fibres. 
Celastrol have not caused significant differences in this marker (Fig 6.1G). 
White blood cell count was also performed at the end of the experiment as a read-out of toxicity. 
Data was compared with a reference range for 8 week old Wistar rats (Table 1). Monocytes and 
eosinophils percentage as well as basophils numbers were between the reference range and there were 
no significant differences between the groups. The percentage of lymphocytes was under the inferior 
limit of the reference range in arthritic-untreated and celastrol at 5 µg/g/day groups however, the group 
treated with 7.5 µg/g/day of the compound showed a tendency to normalize these cells for values 
between the reference range. In contrast, neutrophils percentage were slightly above the reference range 
in all arthritic groups. Although not significantly and not for values between the reference range, animals 
treated with the highest dose of celastrol (7.5 µg/g/day) slightly decreased these levels. Finally, all the 
groups have showed total leukocytes number between the reference range however, those numbers 
showed a tendency to increase in arthritic-untreated group and in celastrol-treated at 5 µg/g/day group 
in comparison with healthy animals. The group treated with 7.5 µg/g/day of celastrol showed a tendency 
to decrease those levels and the difference was even significant between both treated groups (p=0.0190). 
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Figure 6.1 – Evaluation of celastrol’s toxicity: in vivo body weight measurement and blood 
toxicological parameters. (A) Body weight evaluation during celastrol administration. Arthritic-
untreated animals had a significant weight loss when compared to healthy rats that started at the 7th 
day (p=0.0142). Celastrol at 5 µg/g/day did not cause a significant reduction of body weight during the 
experimental course. Animals in celastrol at 7.5 µg/g/day treated group experienced a significant 
reduction of their body weight in day 11 and 13 in comparison with the 4th day (p=0.0103 and p=0.0087 
in day 11 and day 13 in comparison with day 4, respectively) and with the 7th day (p=0.0050 and 
p=0.0102 in day 11 and day 13 in comparison with day 4, respectively)(*).The arrows indicate the days 
when the reduction of body weight was higher than 20% in comparison with the 4th day, implying the 
euthanisia of that animals. At the end of the experiment, animals in both celastrol-treated groups have 
showed a tendency to increase their body weight in comparison with the arthritic-untrated group (B). 
Blood toxicological parameters such as urea (C), ALT (D), LDH (E), CK (F) and Pro-ANP (G) were 
measured. No evidence of drug-induced liver or renal injury was seen in any condition but LDH is 
significantly increased in celastrol 7.5 µg/g/day treated group in comparion with all the other groups 
(p=0.0177, p=0.0062 and p=0.0317 in celastrol 7.5 µg/g/day treated group vs healthy, arthric-
untreated and celastrol 5 µg/g/day treated groups, respectively) and CK is significantly higher in both 
treated groups in comparison with healthy animals (p=0.0221 and p=0.0303 in celastrol 5 µg/g/day 
and 7.5 µg/g/day treated groups vs healthy group, respectively). Differences were considered 
statistically significant for p-values<0.05 (*). All data are expressed as Median with interquartile range. 
Healthy N=8, arthritic-untreated N=10, celastrol at 5 μg/g/day treated group N=6, celastrol at 7.5 
μg/g/day treated group N=6. 
 
Table 1 – Evaluation of celastrol’s toxicity: white blood cell count. At the end of the experiment there 
were no significant differences between the groups in basophils number, eosinophils, monocytes, 
lymphocytes and neutrophils percentage. ns represents non-significance. Despite not significantly, the 
group treated with 7.5 µg/g/day of celastrol showed a tendency to normalize the percentage of 
lymphocytes for values between the reference range. The same group showed a tendency to decrease 
the percentage of neutrophils that were increased in arthritic-untreated and celastrol treated at 5 
µg/g/day groups but not for values between the reference range. Celastrol at 7.5 µg/g/day treated group 
had a significant reduction in leukocytes number in comparison with the group treated with 5 µg/g/day 
(p=0.0190)(#) and a tendency to decrease these cells in comparison with the arthritic-untreated 
group.The reference range correspond to 8 week old Wistar rats (Historical data 2006: Clinical 
laboratories, preclinical services, Charles River Laboratories, Senneville, Canada). 
 
Celastrol-treated 
 Healthy 
Arthritic - 
untreated 
5 µg/g/day 7.5 µg/g/day p-values Reference range 
Leucocytes (*103/µL) 6,8±1,353 10,15±4,02 13,32±4,264 5,425±2,42 p=0.0190# 3,2-12,7 
Neutrophils (%) 19,33±4,726 39,29±10,69 39,33±13,06 34,75±2,63 ns 6,8-31,1 
Lymphocytes (%) 77,33±4,933 59,38±13,26 57,33±13,75 61,5±3,697 ns 60,2-95,0 
Monocytes (%) 2,333±0,5774 3,375±0,5175 3±1,095 3,25±1,258 ns 0,0-4,3 
Eosinophils (%) 1±0 0,875±0,8345 0,3333±0,5164 0,5±0,5774 ns 0,2-5,9 
Basophils (/µL) 0±0 0±0 0±0 0±0 ns 0,0-0,3 
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DISCUSSION 
 
RA is a chronic auto-immune inflammatory disease which mainly affects the small joints and, as 
the disease progresses, can spread to the larger ones. It is characterized by abnormal synovial hyperplasia 
with marked pannus formation and subsequent invasion and destruction of cartilage and bone [163-165]. 
Though it still is an uncurable disease, the treatment of RA significantly improved in the last 20 years 
with the development of new therapies and some patients can even achieve remission. However, the 
various side effects, lack of efficacy in both inflammation and bone, expensive costs and hypersensitivity 
limit their continuous use [166, 167]. Thus, new anti-arthritic therapeutic products are being sought. 
Nowadays, a number of herbal formulations and their active ingredients has gained interest in the 
protection against RA [124]. Celastrol, a bioactive compound from the Chinese plant Trypterigium 
wilfordii Hook F., has been characterized by our group, and others, as a powerful anti-inflammatory and 
bone protective agent [129, 131, 145, 168]. Thus, it has been considered as a promising candidate for 
drug development for the treatment of RA. After proving celastrol’s benefic properties for the treatment 
of arthritis in AIA rat model when intraperitoneal administered in the early and established phase of the 
disease [146], our group have been focused on evaluating dose-related efficacy and toxicity of oral 
administrated celastrol, using the same rat model of arthritis. 
Oral administration of drugs is easy and painfull being for these reasons the most acceptable route 
by patients and therefore the most sought in drug design programmes. In line with this considerations, 
the present project focused on testing the anti-arthritic properties and possible side effects of celastrol 
when orally administered by gavage (intragastric delivery). Since celastrol has poor water solubility, the 
use of an organic solvent is imperative. Dimethylsulphoxide (DMSO), despite being one of the most 
used solvent vehicle in both in vivo and in vitro models [169-171], has been notified with some toxic 
effects when intragastrically administered [162]. In addition, it has been documented its capability of 
inhibit osteoclasts formation, property that can confound the biological readout of anti-arthritic drugs 
[172].  These findings limit the use of DMSO as a solvent for the oral administration of celastrol. 
Ethanol, another recommended solvent for celastrol, has been widely used for oral preparations of 
celastrol [159, 173, 174] and have been demonstrated as one of the best solvents for the compound 
[175]. 
 To evaluate ethanol as a vehicle in this experimental set-up, we used 3 groups of AIA rats. One 
group of arthritic animals received ethanol 17% in PEG400 during 14 days (arthritic EtOH+). This group 
was compared with a group of arthtiric animals who did not receive ethanol (arthritic EtOH-) and with 
healthy rats. The percentage of ethanol applied (17%) was the one used on the highest dose of celastrol 
(7.5 µg/g/day) preparation. We have observed that both arthritic groups did not have a significant 
difference in inflammatory signs of arthritis as validated by inflammatory and global disease severity 
scores as well as ankle swelling, assessed during this experiment. Moreover, animals in arthritic EtOH+ 
group did not lose more weight than the arthritic EtOH- group suggesting that there is no ethanol-
associated toxicity. These observations suggest that the administration of ethanol does not affect the 
course of the disease, and thus it is possible to further evaluate the properties of celastrol using this 
solvent as a vehicle. 
 To explore the effects of celastrol when orally administered in the AIA rat model, two groups of 
arthritic animals received 5 µg/g or 7.5 µg/g of celastrol daily, starting 8 days after disease induction, at 
the beginning of the acute clinical stage of the disease, and was maintained for 14 days until day 22, the 
end of the experiment. The study of Zhang et al [159] allowed the choice of the oral doses to administer 
in this set-up. The present work only presents the results of two of those doses (5 and 7.5 µg/g/day). 
Healthy and arthritic controls received water and vehicle (ethanol 17% in PEG400) by gavage, 
respectively. Both doses of celastrol were able to halt the progression of the disease and the group of 
animals treated with the highest dose (7.5 µg/g/day) showed a tendency to decrease their inflammatory 
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signs of arthritis from day 15. At the end of the experiment, the improvement of inflammatory signs was 
also validated by the reduction of ankle swelling observed in both celastrol-treated groups.  
 One of the most important features of AIA is chronic synovitis including marked infiltration and 
proliferation of perivascular soft tissues with a mixed inflammatory cell infiltrate, present throughout 
the disease course [155]. Our histopathologic evaluation of the left hind paw confirmed that condition.  
Notably, both doses of celastrol were able to significantly decrease synovial sublining layer cell 
infiltration as well as lining layer cellular proliferation in comparison with the arthritic-untreated group. 
To further evaluate the anti-proliferative effects of celastrol, we stained the left hind paw for ki67, a 
marker of cell proliferation. We have observed that celastrol significantly reduced cellular proliferation 
in the synovia in both doses. These results are entirely consistent with our previous results that unveiled 
that intraperitoneal administration of celastrol decrease Mφ and lymphocyte infiltration as well as cell 
proliferation [146]. Additionally, it was documented that celastrol is able to reduce several chemokines 
in the synovia impairing the migration of leukocytes [147] and FLS [144]. 
Previous studies in AIA rats have shown that skeletal erosions begins one or two days after the 
paw swelling, associated with acute synovitis, and bone damage increases rapidly over time [155]. In 
order to assess the influence of celastrol in bone, we evaluated markers and mediators of bone formation 
and resorption. Osteocalcin, a protein synthesized by osteoblasts during the late stage of maturation, is 
responsible for the calcium binding in bone matrix [176], was used as a marker of osteoblasts. Arthritic-
untreated rats have shown a higher number of osteoblasts producing osteocalcin than healthy animals. 
Celastrol in both doses significantly decreased that production for healthy levels. To further validate 
these tendency, we quantified the levels of P1NP, a peptide generated from newly synthesized collagen 
type I that is released into the serum at the moment of bone formation [102, 177]. The same trend as 
osteocalcin was observed. Both doses of the compound were able to restore osteoblasts number and 
P1NP for healthy levels. In order to evaluate the effect of celastrol in bone resorption we analyzed bone 
resorption markers. Cathepsin K, a bone matrix degradation enzyme produced by osteoclasts and 
responsible for cleaving collagen type I, was used as a local marker of resorbing osteoclasts [178]. The 
number of resorbing osteoclasts was also significantly increased in arthtiric-untreated animals in 
comparison with healthy controls and both celastrol-treated groups have significantly decreased the 
number of these cells. Although it was not significant, serum levels of CTX-I, a peptide resulting from 
the cleavage of collagen type I by cathepsin K which is released into the serum at the moment of bone 
resorption [102, 177], showed a tendency to decrease in both celastrol-treated groups in comparison 
with the arthritic-untreated group. The increased levels in bone formation markers in arthritic-untreated 
animals reflects the compensatory mechanism of bone formation in detriment of the intense bone 
resorption caused by disease condition. This is in accordance with the evidence that arthritis induces 
high bone turnover [101]. Both dose regimens significantly reduced all bone turnover markers and 
mediators to similar levels of healthy animals, with the exception of CTX-I but still have showed a 
tendency towards a decrease. This might suggest that this compound counteracts the inflammation-
driven imbalance between bone formation and bone resorption replacing bone homeostasis. Moreover, 
it was observed that TRAcP 5b, an enzyme secreted by both resorbing and nonresorbing osteoclasts that 
is relased into the serum and therefore considered as a marker of osteoclasts number [179, 180], was 
significantly reduced in both celastrol-treated in comparison with arthritic-untreated animals. This 
suggest that celastrol is capable of decrease the total number of osteoclasts in the joints. The absence of 
significant differences between healthy and arthritic-untreated animals is explained by studies from 
Stolina et al. [157, 181] which report an increase in TRAcP 5b locally in the joints but not systemically. 
The histopathologic evaluation corroborates the previous results revealing that animals from both treated 
groups displayed less erosions than the arthritic-untreated group. This may suggest that the compound 
stops bone damage.  
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 In fact, Idris Al et al [182] have proved in bone marrow macrophages that celastrol is capable of 
inhibiting RANKL-stimulated osteoclast formation and induce their apoptosis in vitro. Accordingly, 
Gan K et al [183] have found that celastrol suppresses the expression of NFATc1, the master 
transcription factor for osteoclast differentiation in CIA mice and in RAW264.7 macrophage cell line. 
Furthermore, several studies have proved that celastrol decreases RANKL levels both in serum and in 
the joints, reducing RANKL/OPG ratio [145], in favour of OPG, and reduce pro-inflammatory 
mediators that drive osteoclastogenesis, such as IL-17, IL-6, TNF and IL-1 and MMP-9 [131, 146]. It is 
also known that celastrol is able to inactivate the NFκB signaling pathway, that in turn, plays a central 
role in regulating osteoclastic differentiation and bone resorption [131, 184].  
These improvements both in inflammation and in bone erosions were validated by global disease 
severity score, which have shown a significant decrease in both treated groups in comparison with 
arthritic-untreated animals. In addition, to further validate the efficacy of celastrol for the treatment of 
RA we stained the left hind paw for CD68, a biomarker of sublining macrophages and fibroblasts that 
is substantially decreased in effective RA therapies in an early stage of drug development [185]. 
Notably, both doses of celastrol significantly reduced synovial CD68+ cells in comparison with arthritic-
untreated rats. 
We also investigated possible toxic effects exerted by oral administration of celastrol in vivo. In 
order to do that, the body weight of all animals were assessed during the experiment. Celastrol 
administered at 5 μg/g/day did not caused a significant reduction in body weight throughout the 
experimental course. The group where the compound was administered at the highest dose (7.5 
μg/g/day) have experienced a decrease in body weight since day 7 that remained low until day 17. This 
reduction was even significant at day 11 and 13 in comparison with the 4th and the 7th days. Nevertheless, 
despite the group have showed a tendency to decrese the body weight during the period of treatment 
there was no significant differences between those days and was even a tendency to increase their weight 
since day 17. Two of the animals in this group were euthanized before the end of the experiment due to 
a body weight loss of more than 20% in comparison with day 4. The reduction in body weight in 
arthritic-untreated rats is explained by the disease and is well documented in several reports [155, 186]. 
However, not all the studies that evaluate the efficacy of celastrol reveal data about toxicity. Additionaly, 
the existing data are controversial and the toxic effects observed depend on the dose applied and the 
route of administration. For instance, a study from Lin Zheng et al regarding the evaluation of the 
synergistic effect of celastrol and an approved anti-tumoral drug have showed that celastrol at 4 mg/kg 
intraperitoneally administered every 2 days in monotherapy led to 50% of mortality in mice and induced 
a remarkable body weight loss in the surviving animals [187]. The same side effects were observed by 
Jolanta Konieczny et al in Wistar rats that received 3 mg/kg intraperitoneally of celastrol [188]. In 
contrast, Wei Chang et al administered celastrol at 2, 4 or 8 mg/kg intragastric in rats during 10 weeks 
in order to test the compound in hepatocellular carcinoma and did not find any toxic effect. In fact, the 
study reports the improvement of the hepatic condition in all celastrol-treated groups as well as a 
protective effect on the liver at 2 and 4 mg/kg of the compound in comparison with untreated rats [189]. 
The fact that the previous study, and others [126, 173, 182, 190, 191], did not show toxic effects caused 
by celastrol, even at higher doses, could be the result of the low bioavailability of the compound when 
orally administered [159]. Poor absortion implies a low concentration of the drug in the bloodstream 
and consequently possible less side effects.  However, the body weight lost and the early death of two 
animals in celastrol at 7.5 μg/g/day treated group should not be overlooked and suggest that further 
studies should be conducted with doses under 7.5 μg/g/day. 
Several blood biochemical markers were used to evaluate tissue damage induced by celastrol 
treatment. Tests to urea and alanine transaminase revealed no celastrol induced renal- or hepatic-toxicity 
in both doses. However, the significant increase in lactate dehydrogenase in the group treated with the 
highest dose of the compound (7.5 μg/g/day) in comparison with the arthritic-untreated group suggest 
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tissue injury associated to the administration of the compound at this dose. Moreover, creatine kinase 
(CK) was significantly elevated in celastrol both treated groups, in comparison with the healthy group. 
Despite there was no significant difference between both treated and arthritic-untreated groups, there 
was a trend towards an increase in treated groups suggesting that this inherent toxicity is due to the drug 
and not disease associated. High levels of CK are an indication of muscle injury and has been associated 
with rhabdomyolysis, myocardial infarction, myositis and myocarditis [192]. The results of the 
histopathological study of tissue sections performed by a pathologist will further develop this analysis. 
We observed that celastrol provoke no cardiac dysfunction, as detected in pro-ANP serum analysis.  
Circulating white blood cell populations were also quantified at the last day of the experiment. 
There was not significantly differences between all the groups in monocytes and eosinophils percentage 
as well as basophils numbers and this values were between the reference range. The percentage of 
lymphocytes was under the inferior limit of the reference range in arthritic-untreated and celastrol at 5 
µg/g/day groups however, the group treated with 7.5 µg/g/day of the compound showed a tendency to 
normalize these cells for values between the reference range. Regarding neutrophils percentage, all the 
arthritic groups were above the reference range and there were no significantly differences between 
them. However, the group treated with celastrol at 7.5 μg/g/day showed a tendency to decrease the 
percentage of these cells. In addition, celastrol at 7.5 µg/g/day treated group showed a tendency to 
decrease the number of leukocytes that was above reference range in the other arthritic groups. To sum 
up, we did not find evidences of toxic effects in circulating leukocytes caused by celastrol.  
Taken together, the present study shows that celastrol orally administered at 5 or 7.5 µg/g/day has 
anti-arthritic effects in AIA Wistar rats since reduce both joint inflammation and bone erosions.  The 
compound reduced the number of osteoclasts as well as osteoblasts to basal levels. These data is in line 
with our previous publication, showing that celastrol reduces bone turnover. However, celastrol at 7.5 
µg/g/day treated group have showed a significant reduction of body weight, that implied the euthanasia 
of two animals before the end of the experiment, and a significant increase in lactate dehydrogenase 
(indicator of tissue damage) in comparison with the arthritic-untreated group. These outcomes impair 
the use of this dose in further studies. The other dose assessed in this project (5 µg/g/day) did not present 
significant toxic effects when compared with the arthritic-untreated animals and possible muscle injury, 
observed by the increased levels of creatine kinase in comparison with healthy rats is under a specific 
analysis performed by a pathologist. Future investigations conducted by our group will complete the 
present study establishing a more extensive preclinical analysis of celastrol. Moreover, in order to 
improve celastrol’s bioavailability and therefore reduce the amount of administered compound 
necessary to achieve a desired pharmacological effect with reduced toxicity, the use of nanocarriers 
should be considered. 
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APPENDIX 
 
 
 
1. Inflammatory score throughout disease progression in arthritic EtOH+ and EtOH- rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1.1 – Inflammatory score throughout disease progression in arthritic EtOH+ and EtOH- 
rats.  There were no significant differences in inflammatory signs of arthritis throughout disease 
progression between the rats that orally received ethanol 17% in PEG400 and the ones that did not. 
The arrow indicates the first day of administration. Bars represent standard error of the mean. Healthy 
N=8, arthritic EtOH+ N=15 and arthritic EtOH- N=5. 
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2. Body weight throughout disease progression in arthritic EtOH+ and EtOH- rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2.1 – Body weight throughout disease progression in arthritic EtOH+ and EtOH- rats.  
There were no significant differences throughtout the disease course in body weight between the rats 
that orally received ethanol 17% in PEG400 and the ones that did not. Bars represent standard error 
of the mean. Healthy N=8, arthritic EtOH+ N=15 and arthritic EtOH- N=5. 
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3. Body weight throughout disease progression in celastrol-treated AIA rats 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3.1 – Body weight throughout disease progression in celastrol-treated AIA rats.  There were 
no significant differences throughtout the disease course in body weight in celastrol at 5 µg/g/day 
treated group (A). Animals treated with 7.5 µg/g/day of celastrol lost significantly more weight by day 
11 and 13 when compared with the 4th  day (p=0.0103 and p=0.0087 in day 11 and day 13 in comparison 
with day 4, respectively) and with the 7th day (p=0.0050 and p=0.0102 in day 11 and day 13 in 
comparison with day 4, respectively) (B). Differences were considered statistically significant for p-
values<0.05 (*). Data are expressed as Median with interquartile range. Healthy N=8, arthritic-
untreated N=10, celastrol at 5 μg/g/day treated group N=6, celastrol at 7.5 μg/g/day treated group 
N=6. 
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